Definitive Contract 75N93024C00024
Award Date
9/30/24
Potential Completion Date
9/29/29
Potential Value
$10M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
University Of Montana
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Missoula, MT 59812, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
13
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
This is a $9,013,936.11 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to the Icahn School of Medicine at Mount Sinai. The contract is part of NIAID's Vaccine Adjuvant Discovery Program and aims to identify novel adjuvant candidates that can be used to enhance the efficacy of human vaccines. The contract has no set-aside designation. Key subcontractors include The Scripps Research Institute,...
This is a $9,807,060 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the University of Chicago. The contract is for the Vaccine Adjuvant Discovery Program (VADP), which aims to evaluate and develop animal and animal replacement models for screening and assessing candidate countermeasures such as therapeutics, vaccines, and diagnostics. This contract is not set-aside and is a cost-type...
This is a $10,725,896 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Oregon Health & Science University (OHSU) to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. The contract supports research to develop new vaccine adjuvants that leverage the innate and adaptive immune system to enhance protection against pathogens relevant to human disease. The contract does not have a set-aside designation....
This is a $7,143,498.00 firm fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Maryland, Baltimore (UMB) with a completion date of September 29, 2028. The contract does not have a set-aside designation. The award involves the development of an adjuvant, the TLR4 ligand BECC470S, which is a key component in vaccine formulations. UMB is the prime contractor, with the University of Missouri System and the Washington...
This federal contract award, valued at $10,517,896.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of California, San Diego (UCSD). The award is part of NIAID's Vaccine Adjuvant Discovery Program (VADP), which supports the identification and characterization of novel, effective, and safe vaccine adjuvants. The contract does not have a set-aside designation. UCSD will lead the research efforts, which will focus on four key areas: (1)...
This federal contract award, valued at $5,822,726.00, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Duke University. The contract is for the "ADJUVANT COMPARISON AND CHARACTERIZATION" project, which aims to compare multiple vaccine adjuvants using various vaccine and antigen platforms through comprehensive immune assessments. The contract does not have a set-aside designation. This contract is part of a broader NIAID program that seeks to...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to The Leland Stanford Junior University (Stanford University), a private research institution. The $19,155,153 contract is for a 5-year research program to compare multiple vaccine adjuvants and comprehensively assess the immune responses they induce. The goal is to develop "immune fingerprints" of adjuvants using advanced...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID) to Corixa Corporation, a foreign-owned, for-profit manufacturer of goods. The contract, valued at $12,969,028.00, is to establish a pipeline of new adjuvant leads. An adjuvant is a substance that enhances the body's immune response to an antigen. The contract is a definitive contract with a cost-no-fee pricing type and had an ultimate completion date of December 29, 2008. There was no...
This is a $4,259,653.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company, for the development of a synthetic AS01-like adjuvant system for influenza vaccines. The contract has an ultimate completion date of September 29, 2028 and is a cost-type contract without a fee. This contract is not set aside for...